Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


August 27, 2015 9:29 PM ET

Pharmaceuticals

Company Overview of Alvine Pharmaceuticals, Inc.

Company Overview

Alvine Pharmaceuticals, Inc., a clinical stage company, develops biologics to target autoimmune/inflammatory diseases. It offers ALV003, a mixture of gluten-specific recombinant proteases for the treatment of celiac disease; proteases; tTG Inhibitors, a multifunctional protein with enzymatic, cell signaling, and cell adhesion activities; and HLA-DQ2 Blockers, a class II heterodimer of human leukocyte antigen. The company was incorporated in 2005 and is based in San Carlos, California.

75 Shoreway Road

Suite B

San Carlos, CA 94070

United States

Founded in 2005

Phone:

650-596-2434

Fax:

650-637-3396

Key Executives for Alvine Pharmaceuticals, Inc.

Chief Executive Office, President and Director
Scientific Founder and Director
Age: 50
Senior Director of Finance
Chief Business Officer and Senior Vice President
Chief Medical Officer and Senior Vice President of Development
Age: 58
Compensation as of Fiscal Year 2015.

Alvine Pharmaceuticals, Inc. Key Developments

Alvine Pharmaceuticals, Inc. Doses First Patient in Phase 2b Trial for ALV003 in Celiac Disease

Alvine Pharmaceuticals, Inc. announced that the first randomized study patient was dosed in the CeliAction Study(TM), a phase 2b study of its lead clinical candidate, ALV003, which is in development for the treatment of patients with celiac disease. ALV003 is an orally administered mixture of two gluten-specific proteases shown in vitro to degrade gluten, the primary immunologic trigger for celiac disease. The CeliAction Study(TM), a phase 2b, randomized, double-blind, placebo-controlled, dose-ranging clinical study will evaluate the safety and efficacy of ALV003 at different dose levels administered over a twelve-week period in approximately 500 patients in the United States, Canada and Europe. The study is currently enrolling diagnosed celiac disease patients who are symptomatic despite attempting to follow a gluten-free diet. The study will evaluate the safety and efficacy of ALV003 administered over a twelve-week period; patients must remain on a gluten-free diet during the study. The primary efficacy endpoint for the study is the change in small intestinal mucosal morphology as measured by the change in villus height to crypt depth ratio (Vh:Cd) from baseline and week 12 assessments. Secondary endpoints are the changes in density in intestinal intraepithelial lymphocytes and celiac disease-specific symptoms during the study.

Similar Private Companies By Industry

Company Name Region
Abeille Pharmaceuticals, Inc. United States
CG Nutritionals, Inc. United States
NT Pharma, LLC United States
Nutrition Formulators, Inc. United States
Pharmacia LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Alvine Pharmaceuticals, Inc., please visit www.alvinepharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.